How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration

被引:214
作者
Zhou, AW [1 ]
Huntington, JA [1 ]
Pannu, NS [1 ]
Carrell, RW [1 ]
Read, RJ [1 ]
机构
[1] Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England
基金
美国国家卫生研究院; 英国惠康基金; 英国医学研究理事会;
关键词
D O I
10.1038/nsb943
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The interaction of the plasma protein vitronectin with plasminogen activator inhibitor-1 (PAI-1) is central to human health. Vitronectin binding extends the lifetime of active PAI-1, which controls hemostasis by inhibiting fibrinolysis and has also been implicated in angiogenesis. The PAI-1 vitronectin binding interaction also affects cell adhesion and motility. For these reasons, elevated PAI-1 activities are associated both with coronary thrombosis and with a poor prognosis in many cancers. Here we show the crystal structure at a resolution of 2.3 Angstrom of the complex of the somatomedin B domain of vitronectin with PAI-1. The structure of the complex explains how vitronectin binds to and stabilizes the active conformation of PAI-1. It also explains the tissue effects of PAI-1, as PAI-1 competes for and sterically blocks the interaction of vitronectin with cell surface receptors and integrins. Structural understanding of the essential biological roles of the interaction between PAI-1 and vitronectin opens the prospect of specifically designed blocking agents for the prevention of thrombosis and treatment of cancer.
引用
收藏
页码:541 / 544
页数:4
相关论文
共 33 条
[1]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[2]   Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization [J].
Bajou, K ;
Noël, A ;
Gerard, RD ;
Masson, V ;
Brunner, N ;
Holst-Hansen, C ;
Skobe, M ;
Fusenig, NE ;
Carmeliet, P ;
Collen, D ;
Foidart, JM .
NATURE MEDICINE, 1998, 4 (08) :923-928
[3]   MOLECULAR EVOLUTION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 FUNCTIONAL STABILITY [J].
BERKENPAS, MB ;
LAWRENCE, DA ;
GINSBURG, D .
EMBO JOURNAL, 1995, 14 (13) :2969-2977
[4]   Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins [J].
Czekay, RP ;
Aertgeerts, K ;
Curriden, SA ;
Loskutoff, DJ .
JOURNAL OF CELL BIOLOGY, 2003, 160 (05) :781-791
[5]   Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? [J].
Deng, G ;
Curriden, SA ;
Wang, SJ ;
Rosenberg, S ;
Loskutoff, DJ .
JOURNAL OF CELL BIOLOGY, 1996, 134 (06) :1563-1571
[6]   The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent [J].
Devy, L ;
Blacher, S ;
Grignet-Debrus, C ;
Bajou, K ;
Masson, R ;
Gerard, RD ;
Gils, A ;
Carmeliet, G ;
Carmeliet, P ;
Declerck, PJ ;
Noël, A ;
Foidart, JM .
FASEB JOURNAL, 2002, 16 (02) :147-154
[7]   An extensively modified version of MolScript that includes greatly enhanced coloring capabilities [J].
Esnouf, RM .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 1997, 15 (02) :132-+
[8]  
Gils A, 2002, THROMB HAEMOSTASIS, V88, P137
[9]   Clinical relevance of the plasminogen activator inhibitor type 1 -: a multifaceted proteolytic factor [J].
Harbeck, N ;
Krüger, A ;
Sinz, S ;
Kates, RE ;
Thomssen, C ;
Schmitt, M ;
Jänicke, F .
ONKOLOGIE, 2001, 24 (03) :238-244
[10]  
HEKMAN CM, 1985, J BIOL CHEM, V260, P11581